Saito Wakana, Nagai Hideaki, Suzuki Junko, Masuda Kimihiko, Tamura Atsuhisa, Nagayama Naohiro, Akagawa Shinobu, Kawabe Yoshiko, Machida Kazuko, Kurashima Atsuyuki, Yotsumoto Hideki, Saito Tsuyoshi, Arai Tomo, Okabe Nobuhiko
Department of Respiratory, National Hospital Organization Tokyo Hospital.
Nihon Kokyuki Gakkai Zasshi. 2005 May;43(5):277-82.
We investigated the antibody response to a 23-valent pneumococcal polysaccharide vaccine (23PSV), in 151 patients (average age: 70 years old) with chronic respiratory disease. Serotype-specific IgG antibodies to 4 pneumococcal capsular polysaccharides (6B, 14, 19F, and 23F) were analyzed by ELISA before, and one month after, 23PSV vaccination in all patients. Patients showed a significant increase in specific IgG levels to Streptococcus pneumoniae after 23PSV vaccination (5.5 times-20.9 times). Even patients aged over 80, patients with respiratory failure, and patients receiving corticosteroid therapy developed a significant immunologic response to 23PSV. Local pain or induration occurred in 9.1-14.3% and fatigue or chills occurred in 0.7-6.5% of patients. All adverse reactions disappeared in 2 or 3 days and there was no severe adverse events. Further studies are needed to confirm the exact protective antibody level and to examine the decline of antibody level after vaccination.
